PCI Welcomes Tadataka Yamada, Former Head of GSK and Takeda R&D, to Board of Directors

Packaging Coordinators Inc. (PCI) is pleased to welcome the addition of Dr Tadataka Yamada to its Board of Directors. Dr Yamada recently rejoined Frazier Healthcare, a principal owner of PCI, as a Venture Partner on the Life Sciences team. Prior to his role with Frazier Healthcare, Dr Yamada served as Chief Medical and Scientific Officer at Takeda Pharmaceuticals in Tokyo, as well as serving on the Takeda Board of Directors. Dr Yamada has also served as President of the Bill & Melinda Gates Foundation Global Health Program, in addition to having served as Chairman of R&D at GlaxoSmithKline, where he also served on the Board of Directors.

“We could not be more pleased to have someone of Dr Tadataka Yamada’s intelligence and experience join our Board of Directors,” states Bill Mitchell, PCI President and CEO. “He brings a level of insight and practical experience that is truly invaluable as we continue to expand the breadth of our service offering to our clients.  Our ongoing strategy is to align our portfolio of services to truly meet our client needs as part of a strategic outsourcing partnership. Dr Yamada understands the pharmaceutical and biotech industry better than anyone. His presence and guidance is a tremendous asset for PCI.”

In late 2014 PCI acquired two adjacent businesses, Penn Pharma and Biotec Services International, significantly expanding its breadth of services and drug development offering. PCI now offers a comprehensive service portfolio which begins at Phase I clinical trial and extends for the entirety of the drug lifecycle, with services including drug manufacturing, clinical trials packaging and logistics, analytical laboratory services, as well as commercial manufacturing and packaging services. With a supply network located across North America and Europe, PCI supports lifesaving medicines destined to over 100 countries globally.